Focus: Bayer is a 100,000-employee global pharmaceutical and chemical giant headquartered in Leverkusen, Germany, with leading portfolios in oncology, cardiovascular, hematology, and ophthalmology. The company operates as a publicly traded entity (BAYRY) with a diversified product mix spanning peak-revenue drugs, late-stage pipeline programs, and established generics.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Bayer offers career depth in established oncology and cardiovascular science but faces near-term restructuring risk and weak hiring momentum; best suited for candidates prioritizing patent-protected stability over growth opportunity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bayer
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bayer's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Anchors 34% of company revenue; cornerstone cardiology asset with 10+ years patent protection remaining.
Second-largest revenue generator; longest patent tail (2042) underscores oncology franchise strength.
Strong cardio-renal indication with solid revenue; 11-year patent runway supports long-term pipeline strategy.
Mid-tier oncology asset with patent protection through 2032.
Mature MS monotherapy approaching loss of exclusivity; 26 active Phase 3 trials signal internal reinvestment efforts.
Post-LOE generic; represents legacy asset with minimal differentiation.
Precision oncology play with 13-year patent protection; supports innovation narrative.
Aging kinase inhibitor; first major patent cliff imminent (2028), marking critical revenue transition point.
Minor generic; represents legacy portfolio with no growth trajectory.
Aging HRT product with approaching LOE; minimal contemporary relevance.
110 discontinued, 90 duplicate formulations not shown
+10 more products with revenue data
Bayer’s August Pivot: A Chinese Regulatory Filing and a Tightening Legal Clock - AD HOC NEWS
Bayer’s August Pivot: A Chinese Regulatory Filing and a Tightening Legal Clock AD HOC NEWS
Bayer Appoints Simon Rosof To Lead Pharmaceuticals Business Across Asia Pacific - CodeBlue
Bayer Appoints Simon Rosof To Lead Pharmaceuticals Business Across Asia Pacific CodeBlue
Bayer opens global innovation network to Korean biotech startups - koreabiomed.com
Bayer opens global innovation network to Korean biotech startups koreabiomed.com
Bayer (XTRA:BAYN) On Henry Ford Health Deal And The Fair Value Question - simplywall.st
Bayer (XTRA:BAYN) On Henry Ford Health Deal And The Fair Value Question simplywall.st
Kairos Pharma Announces Strategic Collaboration With Bayer To Enhance XOFIGO Activity In Metastatic Prostate Cancer - Pulse 2.0
Kairos Pharma Announces Strategic Collaboration With Bayer To Enhance XOFIGO Activity In Metastatic Prostate Cancer Pulse 2.0
Bayer (XTRA:BAYN) Teams Up With Kairos Pharma On Prostate Cancer Combo Study - simplywall.st
Bayer (XTRA:BAYN) Teams Up With Kairos Pharma On Prostate Cancer Combo Study simplywall.st
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Global Perspective on the Evolution and Future of Pharmacovigilance: Deliverables from the 24th Annual Meeting of the International Society of Pharmacovigilance Celebrating 25 Years of Excellence.
Pharmacological treatments and clinical events in newly diagnosed heart failure patients stratified by ejection fraction in Japan.
+51 more products
+2 more
Source: state DOL filings, aggregated via Big Local News
Substantial layoff velocity and concentration in key R&D footprint (Whippany) signal execution risk and organizational volatility; elevated churn likelihood for mid-to-senior individual contributors.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo